Nektar Therapeutics Senior Notes
Nektar Therapeutics (NKTR) had Senior Notes of $254.80 million as of 2020-03-31, per its 10-Q filed 2020-05-08.
Discontinued › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:SeniorNotes · last filed 2020-05-08
- 2020-03-31: Senior Notes $254.80M.
- 2019-12-31: Senior Notes $250.00M.
- 2019-09-30: Senior Notes $250.00M.
- 2019-06-30: Senior Notes $250.00M.
| Period end | Senior Notes |
|---|---|
| 2020-03-31 | $254.80M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $250.00M 10-K · filed 2020-02-28 |
| 2019-09-30 | $250.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $250.00M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $250.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $250.00M 10-K · filed 2019-03-01 |
| 2018-09-30 | $250.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $250.00M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $250.00M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $250.00M 10-K · filed 2018-03-01 |
| 2017-09-30 | $250.00M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $250.00M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $250.00M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $250.00M 10-K · filed 2017-03-01 |
| 2016-09-30 | $250.00M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $250.00M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $250.00M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $250.00M 10-K · filed 2016-02-29 |
| 2012-07-11 | $125.00M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |